Company Encyclopedia
View More
name
Bohui Innovation
300318.SZ
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others.
893.67 B
300318.SZMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking56/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.51%D
    • Profit Margin-5.76%D
    • Gross Margin39.33%B
  • Growth ScoreD
    • Revenue YoY-5.76%D
    • Net Profit YoY-213.29%E
    • Total Assets YoY5.11%C
    • Net Assets YoY-4.07%D
  • Cash ScoreE
    • Cash Flow Margin-1735.15%E
    • OCF YoY-5.76%D
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreC
    • Gearing Ratio47.10%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bohui Innovation released its performance for the first three quarters, with a net loss attributable to the parent company of 33.6152 million yuan

    According to the Zhitong Finance APP, Bohui Innovation released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 629 million yuan, a year-on-year decrease of 2.68%. The net loss attributable to shareholders of the listed company was 33.6152 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 18.73 million yuan. The basic loss per share was 0.0411 yuan

    Zhitong·
    SZ
    300318
    -1.56%
    Zhitong·
    SZ
    300318
    -1.56%

    Bohui Innovation: Net loss of 18.6882 million yuan in the first half of 2025

    Bohui Innovation announced that in the first half of 2025, operating revenue was 404 million yuan, a year-on-year decrease of 17.03%. The net loss was 18.6882 million yuan, compared to a net profit of 27.6338 million yuan in the same period last year

    Zhitong·
    SZ
    300318
    -1.56%
    Zhitong·
    SZ
    300318
    -1.56%

    Bohui Innovation: Human Papillomavirus Genotyping (Type 28) Detection Kit (Chip Hybridization Method) Obtains Medical Device Registration Certificate

    Bohui Innovation recently obtained the medical device registration certificate issued by the National Medical Products Administration, involving the human papillomavirus genotyping (type 28) detection kit (chip hybridization method). The acquisition of this registration certificate will enrich the company's product variety, enhance core competitiveness and market expansion capabilities, and is of significant importance for future performance improvement

    Zhitong·
    SZ
    300318
    -1.56%
    Zhitong·
    SZ
    300318
    -1.56%

    Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit

    Beijing Bohui Innovation Biotechnology received regulatory approval from China's medical products administrator for a third class in vitro diagnostic reagent. The nucleic acid detection kit targets rotavirus, norovirus, enteric adenovirus, astrovirus and sapovirus in stool samples, according to a May 31 filing with the Shenzhen bourse. The certificate is valid until May 28, 2030.

    Trading View·
    SZ
    300318
    -1.56%
    Trading View·
    SZ
    300318
    -1.56%

    Bohui Innovation has obtained a medical device registration certificate

    According to the Zhitong Finance APP, Bohui Innovation announced that the company recently obtained the "Medical Device Registration Certificate (In Vitro Diagnostic Reagents)" issued by the National Medical Products Administration. The product name is: Nucleic Acid Detection Kit for Rotavirus, Norovirus, Enteric Adenovirus, Astrovirus, and Sapovirus (PCR-Fluorescent Probe Method)

    Zhitong·
    SZ
    300318
    -1.56%
    Zhitong·
    SZ
    300318
    -1.56%
    © 2025 Longbridge｜Disclaimer